Changes to the gut microbiome resulting from acarbose treatment are associated with increased longevity in mice
New preprint posted to the bioRxiv
I'm excited to announce that we've posted a preprint of our latest manuscript to the bioRxiv, as well as submitted it for peer review to the open access journal Microbiome. I'll update this note if and when it gets accepted.
Edit 2019-06-20: Our submission to Microbiome was tranferred to BMC Microbiology, and was finally accepted (more than a full year in review!). Check it out in print.
These days it seems like the only research more over-hyped than "microbiome" is longevity-enhancement. It is therefore with some trepidation that I have released into this world of buzz the first chapter of my dissertation, titled: "Changes in the gut microbiota and fermentation products associated with enhanced longevity in acarbose-treated mice."
Previous work (done by my co-authors on this paper as well as others) has conclusively demonstrated that treatment with the anti-diabetic drug acarbose substantially increases lifespan in mice (also). The magnitude of …